Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Parathyroid hormone exacerbates pulmonary hypertension through hypoxia-induced parathyroid hormone receptor upregulation.

ABSTRACT: Parathyroid hormone exacerbates pulmonary hypertension through hypoxia-induced parathyroid hormone receptor upregulation.

PROVIDER: PRJNA1025021 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR26313750_1.fastq.gz	Fastqsanger.gz
	SRR26313750_2.fastq.gz	Fastqsanger.gz
	SRR26313751_1.fastq.gz	Fastqsanger.gz
	SRR26313751_2.fastq.gz	Fastqsanger.gz
	SRR26313752_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 18

Similar Datasets

Parathyroid hormone exacerbates pulmonary hypertension through hypoxia-induced parathyroid hormone receptor upregulation.

Project description:Pulmonary hypertension (PH) is an incurable right heart failure disease. Parathyroid hormone (PTH) is secreted from the parathyroid gland and plays a crucial role in calcium homeostasis. PTH also acts on the cardiovascular system and affects cardiovascular prognosis. We assessed whether the regulation of PTH affected PH in a hypoxia (Hx)-induced PH mouse model. PTH treatment exacerbated right ventricular hypertrophy and right ventricular systolic pressure in Hx mice. Our data showed how is PTH effected for PH model murine lung.

2023-10-11 | GSE244861 | GEO

Parathyroid Hormone Treatment Effect on Gene Expression in Primary Calvarial Osteoblasts

Project description:The effect of parathyroid hormone (PTH) treatment was tested on osteoblasts prepared from calvaria of C57BL/6J mice 7-10 days old. Osteoblasts were treated with either human parathyroid hormone (1-34), bovine (D-Trp12,Tyr34) parathyroid hormone (7-34) amide or vehicle control for 4 hr. Gene expression effects were evaluated by DNA microarray.

2022-07-28 | GSE181284 | GEO

Effect of Parathyroid Hormone Analog Treatment on Gene Expression

Project description:The effect of parathyroid hormone (PTH) analog treatment was tested on osteoblasts prepared from calvaria of C57BL/6J mice 7-10 days old. Osteoblasts were treated for 4 hr with either human parathyroid hormone (1-34) (hPTH(1-34), bovine (D-Trp12,Tyr34)-PTH(7-34) amide (bPTH(7-34)), bPTH(3-34), hPTH(1-31), or hPTH(7-34). Gene expression effects were evaluated by DNA microarray.

2022-08-02 | GSE181344 | GEO

Long noncoding RNA expression profiles in intermittent parathyroid hormone induced cementogenesis

Project description:The aim of this study was to explore the involvement of long noncoding RNAs (lncRNAs) during intermittent parathyroid hormone (PTH) induced cementogenesis.

2022-07-06 | GSE207523 | GEO

Effect of Parathyroid Hormone Analog Treatment on Gene Expression

Project description:Effect of Parathyroid Hormone Analog Treatment on Gene Expression

| PRJNA751605 | ENA

Transcription profiling of mouse primary osteoblastic cells after intermittent of continuous treatment with parathyroid hormone to investigate the role of beta-arrestin2

Project description:Role of beta-arrestin2 in response to intermittent or continuous parathyroid hormone (PTH) treatment.

2009-07-20 | E-TABM-624 | biostudies-arrayexpress

Parathyroid Hormone Treatment Effect on Gene Expression in Primary Calvarial Osteoblasts

Project description:Parathyroid Hormone Treatment Effect on Gene Expression in Primary Calvarial Osteoblasts

| PRJNA751401 | ENA

Long noncoding RNA expression profiles in intermittent parathyroid hormone induced cementogenesis

Project description:Long noncoding RNA expression profiles in intermittent parathyroid hormone induced cementogenesis

| PRJNA855958 | ENA

Genetic characterization of large parathyroid adenomas

Project description:We genetically characterized parathyroid adenomas with large glandular weights, for which independent observations suggest pronounced clinical manifestations. Large parathyroid adenomas (LPTAs) were defined as the 5% largest sporadic parathyroid adenomas identified among the 590 cases operated on in our institution during 2005-2009. The LPTA group showed a higher relative number of male cases and significantly higher levels of total plasma and ionized serum calcium (P <0.001). Further analysis of 21 LPTAs revealed low MIB-1 proliferation index (0.1-1.5%), MEN1 mutations in 5 cases and one HRPT2 mutation. Total or partial loss of parafibromin expression was observed in 10 tumors, two of which also showed loss of APC expression. Using array-CGH, we demonstrated recurrent copy number alterations most frequently involving loss in 1p (29%), gain in 5 (38%) and loss in 11q (33%). Totally 21 minimal overlapping regions were defined for losses in 1p, 7q, 9p, 11 and 15q, and gains in 3q, 5, 7p, 8p, 16q, 17p and 19q. In addition, 12 tumors showed gross alterations of entire or almost entire chromosomes, most frequently gain of 5 and loss of 11. While gain of 5 was the most frequent alteration observed in LPTAs, it was only detected in a small proportion (4/58 cases, 7%) of parathyroid adenomas. A significant positive correlation was observed between parathyroid hormone level and total copy number gain (r = 0.48, P = 0.031). These results support that LPTAs represent a group of patients with pronounced parathyroid hyperfunction and associated with specific genomic features. We applied high-resolution array-CGH to assess copy number alterations (CNAs) in 21 tumors representing the 5% largest sporadic parathyroid adenomas in our institution.

2012-05-08 | E-GEOD-36511 | biostudies-arrayexpress

Genetic characterization of large parathyroid adenomas

2012-05-09 | GSE36511 | GEO